Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10405189,renal clearance,"The renal clearance of CH, free TCE (f-TCE), and TCA of 2, 2.7, and 38 ml/h/kg, respectively, indicates an efficient reabsorption mechanism for all of these small chlorinated compounds.",Effect of enterohepatic circulation on the pharmacokinetics of chloral hydrate and its metabolites in F344 rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405189/),[ml] / [h·kg],2,11541,DB08809,Dichloroacetic Acid
,10405189,renal clearance,"The renal clearance of CH, free TCE (f-TCE), and TCA of 2, 2.7, and 38 ml/h/kg, respectively, indicates an efficient reabsorption mechanism for all of these small chlorinated compounds.",Effect of enterohepatic circulation on the pharmacokinetics of chloral hydrate and its metabolites in F344 rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405189/),[ml] / [h·kg],2.7,11542,DB08809,Dichloroacetic Acid
,10405189,renal clearance,"The renal clearance of CH, free TCE (f-TCE), and TCA of 2, 2.7, and 38 ml/h/kg, respectively, indicates an efficient reabsorption mechanism for all of these small chlorinated compounds.",Effect of enterohepatic circulation on the pharmacokinetics of chloral hydrate and its metabolites in F344 rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405189/),[ml] / [h·kg],38,11543,DB08809,Dichloroacetic Acid
,28914978,steady-state trough concentrations,"Finally, a 12.5 and 10.6 mg/kg twice-daily DCA dose was optimal in achieving the target steady-state trough concentrations (5-25 mg/L) for EGT carrier and EGT noncarrier children, respectively.",Model Informed Dose Optimization of Dichloroacetate for the Treatment of Congenital Lactic Acidosis in Children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28914978/),[mg] / [l],5-25,32393,DB08809,Dichloroacetic Acid
,18242812,area-under-the-concentration-curve (AUC),"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],0.02,35616,DB08809,Dichloroacetic Acid
,18242812,AUC,"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],0.1,35617,DB08809,Dichloroacetic Acid
,18242812,AUC,"The HEDs for the dosimetrics, area-under-the-concentration-curve (AUC) for total and free DCA in plasma, AUC of DCA in liver and amount of DCA metabolized per day were 0.02, 0.1, 0.1 and 1.0mg/kg day, respectively.",Quantitative evaluation of dichloroacetic acid kinetics in human--a physiologically based pharmacokinetic modeling investigation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18242812/),[mg] / [d·kg],1.0,35618,DB08809,Dichloroacetic Acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),min,86,43672,DB08809,Dichloroacetic Acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),h,3.2,43673,DB08809,Dichloroacetic Acid
,15464428,half-times,"DCA pharmacokinetics showed half-times approximately 86 min for the first intravenous dose of 50 mg/kg, 3.2 h for a subsequent intravenous dose 4-6 h later, and 11 h after continued oral dosing of 12.5-25 mg/kg twice daily.",Chronic treatment of mitochondrial disease patients with dichloroacetate. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15464428/),h,11,43674,DB08809,Dichloroacetic Acid
,1459365,half-life,The decay was exponential with a half-life consistent with that of rat or mouse albumin (approx 24 hr).,"Adduction of hemoglobin and albumin in vivo by metabolites of trichloroethylene, trichloroacetate, and dichloroacetate in rats and mice. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1459365/),h,24,48710,DB08809,Dichloroacetic Acid
,8052155,peak postinfusion level,"The mean +/- SD peak postinfusion level of DCA was 78 +/- 23 mg/L, the total apparent volume of distribution was 0.75 +/- 0.35 L/kg, and systemic clearance was 0.32 +/- 0.16 L/kg/h.",Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8052155/),[mg] / [l],78,52449,DB08809,Dichloroacetic Acid
,8052155,total apparent volume of distribution,"The mean +/- SD peak postinfusion level of DCA was 78 +/- 23 mg/L, the total apparent volume of distribution was 0.75 +/- 0.35 L/kg, and systemic clearance was 0.32 +/- 0.16 L/kg/h.",Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8052155/),[l] / [kg],0.75,52450,DB08809,Dichloroacetic Acid
,8052155,systemic clearance,"The mean +/- SD peak postinfusion level of DCA was 78 +/- 23 mg/L, the total apparent volume of distribution was 0.75 +/- 0.35 L/kg, and systemic clearance was 0.32 +/- 0.16 L/kg/h.",Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8052155/),[l] / [h·kg],0.32,52451,DB08809,Dichloroacetic Acid
,8052155,venous lactate concentrations,"Geometric mean (range) venous lactate concentrations in control and DCA recipients before treatment were 4.5 (2.1 to 19.5) and 5.5 (2 to 15.4) mmol/L, respectively (P > .1).",Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8052155/),[mM] / [l],4.5,52452,DB08809,Dichloroacetic Acid
,8052155,venous lactate concentrations,"Geometric mean (range) venous lactate concentrations in control and DCA recipients before treatment were 4.5 (2.1 to 19.5) and 5.5 (2 to 15.4) mmol/L, respectively (P > .1).",Dichloroacetate for lactic acidosis in severe malaria: a pharmacokinetic and pharmacodynamic assessment. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8052155/),[mM] / [l],5.5,52453,DB08809,Dichloroacetic Acid
,11353629,clearance [CL],A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [h·kg],0.05,61280,DB08809,Dichloroacetic Acid
,11353629,volume of distribution in the central compartment [V(1)],A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [kg],0.65,61281,DB08809,Dichloroacetic Acid
,11353629,volume of distribution at steady state,A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),[l] / [kg],1.41,61282,DB08809,Dichloroacetic Acid
,11353629,half-life at beta phase,A two-compartment model with first-order absorption and elimination gave post hoc estimates for pharmacokinetic parameters that were consistent with those derived from non-population pharmacokinetic studies (clearance [CL] = 0.05 liter/h/kg of body weight; volume of distribution in the central compartment [V(1)] = 0.65 liter/kg; volume of distribution at steady state = 1.41 liter/kg; half-life at beta phase = 19.9 h).,Population pharmacokinetics of intramuscular quinine in children with severe malaria. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11353629/),h,19.9,61283,DB08809,Dichloroacetic Acid
,16611621,bioavailability,"DCAA bioavailability had large interindividual variation, ranging from 27 to 100%.",Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinetics and oral bioavailability in human volunteers: a stable isotope study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16611621/),%,27 to 100,62364,DB08809,Dichloroacetic Acid
,7978471,peak concentrations,"Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 +/- 0.06 (mean +/- SE) and 1.18 +/- 0.09 mM, respectively after the first and second doses.",Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978471/),mM,0.73,88323,DB08809,Dichloroacetic Acid
,7978471,peak concentrations,"Plasma DCA concentration was maintained between 0.28 and 1.18 mM during OLT, with peak concentrations of 0.73 +/- 0.06 (mean +/- SE) and 1.18 +/- 0.09 mM, respectively after the first and second doses.",Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978471/),mM,1.18,88324,DB08809,Dichloroacetic Acid
,7978471,peak,"In control patients, plasma lactate was 1.07 +/- 0.04 at baseline and 1.20 +/- 0.06 before incision and reached a peak of 7.30 +/- 0.41 mM after graft reperfusion.",Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978471/),mM,7.30,88325,DB08809,Dichloroacetic Acid
>,7978471,plasma Na+ concentration,Twelve control and 4 DCA-treated patients exhibited a plasma Na+ concentration > 145 mEq/1 at completion of surgery (P < 0.05).,Amelioration of lactic acidosis with dichloroacetate during liver transplantation in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978471/),meq,145,88326,DB08809,Dichloroacetic Acid
,28163135,rate constant,"The maximum rate constant for DCA-induced GSTZ1-1 inactivation is estimated to be 0.96/h, which is 110 times that of the rate constant for GSTZ1-1 natural degradation (0.00875/h).",A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163135/),1/[h],0.00875,91728,DB08809,Dichloroacetic Acid
,28163135,maximum enzyme inhibition (EC50),The model-predicted DCA concentration that corresponds to 50% of maximum enzyme inhibition (EC50) is 4.32 mg/L.,A Mechanism-Based Pharmacokinetic Enzyme Turnover Model for Dichloroacetic Acid Autoinhibition in Rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28163135/),[mg] / [l],4.32,91729,DB08809,Dichloroacetic Acid
,1878534,terminal elimination half-lives,"A crossover bioavailability study proved abortive because second and subsequent doses showed significantly longer terminal elimination half-lives (means 3.64 h and 9.9 h, respectively) than was the case for initial doses (1.58 h).",Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),h,3.64,93660,DB08809,Dichloroacetic Acid
,1878534,terminal elimination half-lives,"A crossover bioavailability study proved abortive because second and subsequent doses showed significantly longer terminal elimination half-lives (means 3.64 h and 9.9 h, respectively) than was the case for initial doses (1.58 h).",Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),h,9.9,93661,DB08809,Dichloroacetic Acid
,1878534,terminal elimination half-lives,"A crossover bioavailability study proved abortive because second and subsequent doses showed significantly longer terminal elimination half-lives (means 3.64 h and 9.9 h, respectively) than was the case for initial doses (1.58 h).",Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),h,1.58,93662,DB08809,Dichloroacetic Acid
,1878534,AUCoral,"A parallel bioavailability comparison failed to show that oral doses were significantly different from 100 per cent bioavailability (AUCoral, 604 micrograms h-1 ml-1; AUCi.v., 489 micrograms h-1 ml-1).",Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),[μg] / [h·ml],604,93663,DB08809,Dichloroacetic Acid
,1878534,AUCi.v.,"A parallel bioavailability comparison failed to show that oral doses were significantly different from 100 per cent bioavailability (AUCoral, 604 micrograms h-1 ml-1; AUCi.v., 489 micrograms h-1 ml-1).",Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),[μg] / [h·ml],489,93664,DB08809,Dichloroacetic Acid
,1878534,renal clearance,The mean renal clearance of DCA was 42.9 ml h-1.,Disposition and pharmacodynamics of dichloroacetate (DCA) and oxalate following oral DCA doses. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1878534/),[ml] / [h],42.9,93665,DB08809,Dichloroacetic Acid
,8930172,zero-order elimination,"A hybrid, one-compartment pharmacokinetic model fitted best, with zero-order elimination mean of 27.9 micrograms/ml/h at concentrations above about 80 to 120 micrograms/ml, and with first-order elimination (mean kelim = 0.54) at lower serum concentrations of DCA.","Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930172/),[μg] / [h·ml],27.9,107760,DB08809,Dichloroacetic Acid
,8930172,kelim,"A hybrid, one-compartment pharmacokinetic model fitted best, with zero-order elimination mean of 27.9 micrograms/ml/h at concentrations above about 80 to 120 micrograms/ml, and with first-order elimination (mean kelim = 0.54) at lower serum concentrations of DCA.","Reduction of serum lactate by sodium dichloroacetate, and human pharmacokinetic-pharmacodynamic relationships. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930172/),,0.54,107761,DB08809,Dichloroacetic Acid
<,19656582,uptake efficiency,"Branchial uptake efficiency was <5%, suggesting passive diffusion through aqueous channels in the gill epithelium.",Kinetics and effects of dichloroacetic acid in rainbow trout. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656582/),%,5,110554,DB08809,Dichloroacetic Acid
less,19656582,elimination half-lives (t(1/2)),DCA was rapidly cleared by naïve animals resulting in elimination half-lives (t(1/2)) of less than 4h.,Kinetics and effects of dichloroacetic acid in rainbow trout. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19656582/),h,4,110555,DB08809,Dichloroacetic Acid
<,12153755,rate of urinary elimination,Virtually all of the dose was eliminated through metabolic clearance; the rate of urinary elimination was < 1 mL/hr/kg.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),[ml] / [h·kg],1,114318,DB08809,Dichloroacetic Acid
,12153755,Oral bioavailability,Oral bioavailability of DCA was 0-13% in naive and 14-75% in GST-zeta- depleted rats.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,0-13,114319,DB08809,Dichloroacetic Acid
,12153755,Oral bioavailability,Oral bioavailability of DCA was 0-13% in naive and 14-75% in GST-zeta- depleted rats.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,14-75,114320,DB08809,Dichloroacetic Acid
<,12153755,Oral bioavailability,Oral bioavailability of DCA in humans through consumption of drinking water was predicted to be very low and < 1%.,Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta-depleted rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12153755/),%,1,114321,DB08809,Dichloroacetic Acid
,11269566,clearance,"For the pharmacokinetic model, it was discovered that the clearance of DCA decreased on multiple dosing from 4.82 L/h to 1.07 L/h and that the pharmacokinetics and pharmacodynamics in TBI patients could not be predicted from normal volunteers.",Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269566/),[l] / [h],4.82,139385,DB08809,Dichloroacetic Acid
,11269566,clearance,"For the pharmacokinetic model, it was discovered that the clearance of DCA decreased on multiple dosing from 4.82 L/h to 1.07 L/h and that the pharmacokinetics and pharmacodynamics in TBI patients could not be predicted from normal volunteers.",Dichloroacetate: population pharmacokinetics with a pharmacodynamic sequential link model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269566/),[l] / [h],1.07,139386,DB08809,Dichloroacetic Acid
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,0.1,143359,DB08809,Dichloroacetic Acid
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,5.4,143360,DB08809,Dichloroacetic Acid
,9806957,plasma elimination half-lives,"DCA plasma elimination half-lives were 0.1 +/- 0.02 and 5.4 +/- 0.8 hr in young adult rats (180-265 g, 3-4 months of age) given one or two doses of DCA, respectively, and 9.7 +/- 1 hr in large, 16-month-old rats given two DCA doses.","Pharmacokinetics and metabolism of [14C]dichloroacetate in male Sprague-Dawley rats. Identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806957/),h,9.7,143361,DB08809,Dichloroacetic Acid
,7373538,maximum plasma sodium dichloroacetate concentrations,"In three rats, maximum plasma sodium dichloroacetate concentrations were 120-164 microgram/ml after a 100-mg/kg dose and declined with half-lives of 2.1-4.4 hr.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],120-164,158165,DB08809,Dichloroacetic Acid
,7373538,half-lives,"In three rats, maximum plasma sodium dichloroacetate concentrations were 120-164 microgram/ml after a 100-mg/kg dose and declined with half-lives of 2.1-4.4 hr.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),h,2.1-4.4,158166,DB08809,Dichloroacetic Acid
,7373538,maximal concentrations,"In two dogs, maximal concentrations of 447 and 508 microgram/ml were attained after a 100-mg/kg dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],447,158167,DB08809,Dichloroacetic Acid
,7373538,maximal concentrations,"In two dogs, maximal concentrations of 447 and 508 microgram/ml were attained after a 100-mg/kg dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],508,158168,DB08809,Dichloroacetic Acid
,7373538,half-lives,The subsequent decline was relatively slow with approximate half-lives of 17.1 and 24.6 hr.,Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),h,17.1,158169,DB08809,Dichloroacetic Acid
,7373538,half-lives,The subsequent decline was relatively slow with approximate half-lives of 17.1 and 24.6 hr.,Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),h,24.6,158170,DB08809,Dichloroacetic Acid
,7373538,maximum plasma concentrations,"After the infusion, maximum plasma concentrations of 19.9 and 24.7 microgram/ml were seen with the lower dose and 57.3 and 74.9 microgram/ml were achieved with the higher dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],19.9,158171,DB08809,Dichloroacetic Acid
,7373538,maximum plasma concentrations,"After the infusion, maximum plasma concentrations of 19.9 and 24.7 microgram/ml were seen with the lower dose and 57.3 and 74.9 microgram/ml were achieved with the higher dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],24.7,158172,DB08809,Dichloroacetic Acid
,7373538,maximum plasma concentrations,"After the infusion, maximum plasma concentrations of 19.9 and 24.7 microgram/ml were seen with the lower dose and 57.3 and 74.9 microgram/ml were achieved with the higher dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],57.3,158173,DB08809,Dichloroacetic Acid
,7373538,maximum plasma concentrations,"After the infusion, maximum plasma concentrations of 19.9 and 24.7 microgram/ml were seen with the lower dose and 57.3 and 74.9 microgram/ml were achieved with the higher dose.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),[μg] / [ml],74.9,158174,DB08809,Dichloroacetic Acid
,7373538,half-lives,"Thereafter, concentrations declined rapidly with half-lives of 20-36 min.",Biological disposition of sodium dichloroacetate in animals and humans after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7373538/),min,20-36,158175,DB08809,Dichloroacetic Acid
,19409406,bioavailability,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),%,74,160025,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,0.6,160026,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],0.081,160027,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,12,160028,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],3.80,160029,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.4,160030,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],16.8,160031,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.2,160032,DB08809,Dichloroacetic Acid
,19409406,half-life,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],176,160033,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],0.081,160034,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,12,160035,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],3.80,160036,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.4,160037,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],16.8,160038,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),h,1.2,160039,DB08809,Dichloroacetic Acid
,19409406,clearance,"According to the best-fit model, bioavailability of oral TCE was approximately 74%, and the half-life and clearance of each metabolite in the mouse were as follows: DCA: 0.6 h, 0.081 ml/h; TCA: 12 h, 3.80 ml/h; DCVG: 1.4 h, 16.8 ml/h; DCVC: 1.2 h, 176 ml/h.","Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19409406/),[ml] / [h],176,160040,DB08809,Dichloroacetic Acid
,8824690,V,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),[1] / [kg],0.44,185299,DB08809,Dichloroacetic Acid
,8824690,CL,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),[1] / [h·kg],0.13,185300,DB08809,Dichloroacetic Acid
,8824690,Cmax,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),1/[mg1],106,185301,DB08809,Dichloroacetic Acid
,8824690,t1/2,3 An open one-compartment model with the following parameters described the pharmacokinetics of DCA after one dose (mean [s.d.]): V = 0.44(0.2) 1 kg-1; CL = 0.13 [0.027] 1 h-1 kg-1; Cmax = 106[28] mg1-1; t1/2 = 3.4(2.2) h.,The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),h,3.4,185302,DB08809,Dichloroacetic Acid
,8824690,base deficit,"4 DCA decreased venous plasma lactate concentrations by 42% of baseline values 8 h after admission, normalized arterial pH from a mean(s.d.) of 7.367(0.063) to 7.39(0.1), and decreased the calculated base deficit from 9.2(7.3) mEq 1-1 to 6.4(10.4) mEq 1-1.",The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),,9.2,185303,DB08809,Dichloroacetic Acid
,8824690,base deficit,"4 DCA decreased venous plasma lactate concentrations by 42% of baseline values 8 h after admission, normalized arterial pH from a mean(s.d.) of 7.367(0.063) to 7.39(0.1), and decreased the calculated base deficit from 9.2(7.3) mEq 1-1 to 6.4(10.4) mEq 1-1.",The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8824690/),,6,185304,DB08809,Dichloroacetic Acid
,8638839,clearance,"DCA clearance was 0.997, 0.0, and 1.69 ml x kg(-1) x min(-1) during the paleohepatic, anhepatic, and neohepatic periods, respectively (P < 0.05).",Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638839/),[ml] / [kg·min],0.997,193353,DB08809,Dichloroacetic Acid
,8638839,clearance,"DCA clearance was 0.997, 0.0, and 1.69 ml x kg(-1) x min(-1) during the paleohepatic, anhepatic, and neohepatic periods, respectively (P < 0.05).",Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638839/),[ml] / [kg·min],0.0,193354,DB08809,Dichloroacetic Acid
,8638839,clearance,"DCA clearance was 0.997, 0.0, and 1.69 ml x kg(-1) x min(-1) during the paleohepatic, anhepatic, and neohepatic periods, respectively (P < 0.05).",Pharmacokinetics of dichloroacetate in patients undergoing liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8638839/),[ml] / [kg·min],1.69,193355,DB08809,Dichloroacetic Acid
,8971140,terminal half-life,"After intravenous administration, CH rapidly disappeared from blood with a terminal half-life ranging from 5 to 24 min.",Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971140/),min,5 to 24,202421,DB08809,Dichloroacetic Acid
,8971140,Systemic clearance,"Systemic clearance decreased from 36.0 to 7.6 liters/kg-hr with increasing CH dose, demonstrating dose-dependent pharmacokinetics.",Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971140/),[l] / [kg-hr],36.0,202422,DB08809,Dichloroacetic Acid
,8971140,Systemic clearance,"Systemic clearance decreased from 36.0 to 7.6 liters/kg-hr with increasing CH dose, demonstrating dose-dependent pharmacokinetics.",Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971140/),[l] / [kg-hr],7.6,202423,DB08809,Dichloroacetic Acid
,8971140,terminal half-lives,"The terminal half-lives of TCOH and TCOG were similar, ranging from 0.2 to 0.7 hr.",Pharmacokinetic analysis of chloral hydrate and its metabolism in B6C3F1 mice. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971140/),h,0.2 to 0.7,202424,DB08809,Dichloroacetic Acid
,9344886,blood concentration,Pretreatment caused a significant increase in the blood concentration and AUC0-->infinity of DCA (433.3 versus 2406 microg ml-1 hr).,Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344886/),[h·μg] / [ml],433.3,232365,DB08809,Dichloroacetic Acid
,9344886,AUC0-->infinity,Pretreatment caused a significant increase in the blood concentration and AUC0-->infinity of DCA (433.3 versus 2406 microg ml-1 hr).,Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344886/),[h·μg] / [ml],2406,232366,DB08809,Dichloroacetic Acid
,9344886,total body clearance,"Pharmacokinetic analysis indicated that pretreatment significantly decreased total body clearance (267.4 versus 42.7 ml hr-1 kg-1), which was largely due to decreased metabolism since only modest differences in the urinary clearance of DCA were observed.",Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344886/),[ml] / [h·kg],267.4,232367,DB08809,Dichloroacetic Acid
,9344886,total body clearance,"Pharmacokinetic analysis indicated that pretreatment significantly decreased total body clearance (267.4 versus 42.7 ml hr-1 kg-1), which was largely due to decreased metabolism since only modest differences in the urinary clearance of DCA were observed.",Pharmacokinetics and metabolism of dichloroacetate in the F344 rat after prior administration in drinking water. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9344886/),[ml] / [h·kg],42.7,232368,DB08809,Dichloroacetic Acid
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],0. 06,252345,DB08809,Dichloroacetic Acid
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],1.14,252346,DB08809,Dichloroacetic Acid
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],32.8,252347,DB08809,Dichloroacetic Acid
,9356303,Urinary excretion rate constant,"Urinary excretion rate constant values were 0. 06/hr/kg for CH, 1.14/hr/kg for TCOH, 32.8/hr/kg for TCOG, and 1. 55/hr/kg for TCA.","A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],1. 55,252348,DB08809,Dichloroacetic Acid
,9356303,fecal excretion rate constant,A fecal excretion rate constant value for TCOG was 4.61/hr/kg.,"A physiologically based pharmacokinetic model for trichloroethylene and its metabolites, chloral hydrate, trichloroacetate, dichloroacetate, trichloroethanol, and trichloroethanol glucuronide in B6C3F1 mice. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9356303/),1/[h·kg],4.61,252349,DB08809,Dichloroacetic Acid
,9931286,Peak blood TCE concentrations,"Peak blood TCE concentrations were 0.86 and 7.32 microgram/mL, respectively, in mice exposed to 100 and 600 ppm TCE.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),[μg] / [ml],0.86,255053,DB08809,Dichloroacetic Acid
,9931286,Peak blood TCE concentrations,"Peak blood TCE concentrations were 0.86 and 7.32 microgram/mL, respectively, in mice exposed to 100 and 600 ppm TCE.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),[μg] / [ml],7.32,255054,DB08809,Dichloroacetic Acid
,9931286,fractional absorption,"When fractional absorption (53%) of inhaled TCE was incorporated into the model, a comprehensive description of the uptake, distribution, and clearance of TCE in the blood was obtained.",Physiologically based pharmacokinetic modeling of inhaled trichloroethylene and its oxidative metabolites in B6C3F1 mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931286/),%,53,255055,DB08809,Dichloroacetic Acid
,9853003,Metabolic capacity (Vmaxc),Metabolic capacity (Vmaxc) for oxidation of trichloroethylene was estimated to be 4 mg/kg/h in males and 5 mg/kg/h in females.,"A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853003/),[mg] / [h·kg],4,266879,DB08809,Dichloroacetic Acid
,9853003,Metabolic capacity (Vmaxc),Metabolic capacity (Vmaxc) for oxidation of trichloroethylene was estimated to be 4 mg/kg/h in males and 5 mg/kg/h in females.,"A human physiologically based pharmacokinetic model for trichloroethylene and its metabolites, trichloroacetic acid and free trichloroethanol. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9853003/),[mg] / [h·kg],5,266880,DB08809,Dichloroacetic Acid
,7418965,half-life,"At plasma concentrations below 10 micrograms/ml, elimination was monoexponential with a half-life of 32 +/- 11 min (mean +/- SD).",Metabolic effects and pharmacokinetics of intravenously administered dichloroacetate in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7418965/),min,32,266913,DB08809,Dichloroacetic Acid
